Dr. David Chrimes, PhD

David Chrimes has over 12 years experience of developing, commercializing and supporting the use of human genetic disease testing. In 2005, having completed 9 years of academic research in genetic inheritance and gene regulation, David joined BlueGnome to develop and sell best-in-class human genetic analysis solutions to the clinical community with the cytogenetic solution installed and being run in over 80 hospitals and clinic units worldwide by 2012. This technology included the CytoChip array for pre and postnatal investigations and 24sure, the first arrayCGH PGS solution launched in 2008. After the acquisition of BlueGnome by Illumina in Sept 2012, David moved to the position of Associate Director for Bioinformatics within the Reproductive and Genetic Health business unit with the responsibility for the development of genetic analysis software including that used for the analysis of PGD cases by karyomapping. This development was achieved through both direct knowledge but key was through direct customer collaboration and real-life situation projects. David joined Genesis, now part of CooperGenomics, in January 2016 as Director of Business Development to promote the utalisation of reproductive genetic health testing technology and continue to drive innovation to the testing portfolio available to clinics and to match their needs in a society where genetic understanding and the desire for testing is increasing rapidly.

Title of Presentation

Application of PGD in the age of carrier screening

Carrier screening has become a widely available tool to identify couples who have an increased risk of having an affected child and can facilitate informed reproductive decision making. Preimplantation Genetic Diagnosis (PGD) is an established technique for patients who are at risk of transmitting a serious genetic disease to their offspring. Both PGD and carrier screening can improve the live birth rate of healthy offspring. In this talk we will present the application of PGD in the age of carrier screening and discuss the future of this field.